ArticleScientific reports2025

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database.

Yongfu Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.